A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
Zhongling Zhu,1,4 Zhengzi Qian,2,4 Zhao Yan,1,4 Cuicui Zhao,2,4 Huaqing Wang,2,4 Guoguang Ying3,41Department of Clinical Pharmacology, 2Department of Lymphoma, 3Laboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/269f070c524c4278a455d6c1af6beeda |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:269f070c524c4278a455d6c1af6beeda |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:269f070c524c4278a455d6c1af6beeda2021-12-02T05:02:16ZA phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors1176-91141178-2013https://doaj.org/article/269f070c524c4278a455d6c1af6beeda2013-01-01T00:00:00Zhttp://www.dovepress.com/a-phase-i-pharmacokinetic-study-of-ursolic-acid-nanoliposomes-in-healt-a11862https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Zhongling Zhu,1,4 Zhengzi Qian,2,4 Zhao Yan,1,4 Cuicui Zhao,2,4 Huaqing Wang,2,4 Guoguang Ying3,41Department of Clinical Pharmacology, 2Department of Lymphoma, 3Laboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China; 4Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of ChinaBackground: Ursolic acid is a promising anticancer agent. The current study aims to evaluate the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid nanoliposomes (UANL) in healthy volunteers and in patients with advanced solid tumors.Methods: Twenty-four healthy volunteers in the single-dose PK study were divided into three different groups, which received 37, 74, and 98 mg/m2 of UANL. Eight patients in the multiple-dose PK study were administered with 74 mg/m2 of UANL daily for 14 days. The UA plasma concentrations were determined using ultra-performance liquid chromatograph-tandem mass spectrometry.Results: The plasma concentration profiles of all subjects were characterized by a biexponential decline after infusion. The mean peak plasma concentration (Cmax) increased linearly as a function of the dose (r = 0.999). The mean area under the plasma concentration-time curve (AUC) from 0 to 16 hours also increased proportionally with dose escalation (r = 0.998). However, the clearance was constant over the specific dose interval. In the multiple-dose PK study, the trough and average concentrations remained low. The mean AUC, half-life, Cmax, time to Cmax, and the volume of distribution on the first day were similar to those on the last day. All subjects tolerated the treatments well. Most UANL-associated adverse events varied from mild to moderate.Conclusions: UANL exhibits relatively linear PK behavior with dose levels from 37 mg/m2 to 98 mg/m2. No drug accumulation was observed with repeated doses of UANL. The intravenous infusion of UANL was well tolerated by healthy volunteers and patients with advanced tumors.Keywords: ursolic acid, nanoliposomes, pharmacokinetics, solid tumor, ultra-performance liquid chromatography, tandem mass spectrometryYing GWang HZhao CYan ZQian ZZhu ZDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 129-136 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Ying G Wang H Zhao C Yan Z Qian Z Zhu Z A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| description |
Zhongling Zhu,1,4 Zhengzi Qian,2,4 Zhao Yan,1,4 Cuicui Zhao,2,4 Huaqing Wang,2,4 Guoguang Ying3,41Department of Clinical Pharmacology, 2Department of Lymphoma, 3Laboratory of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China; 4Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of ChinaBackground: Ursolic acid is a promising anticancer agent. The current study aims to evaluate the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid nanoliposomes (UANL) in healthy volunteers and in patients with advanced solid tumors.Methods: Twenty-four healthy volunteers in the single-dose PK study were divided into three different groups, which received 37, 74, and 98 mg/m2 of UANL. Eight patients in the multiple-dose PK study were administered with 74 mg/m2 of UANL daily for 14 days. The UA plasma concentrations were determined using ultra-performance liquid chromatograph-tandem mass spectrometry.Results: The plasma concentration profiles of all subjects were characterized by a biexponential decline after infusion. The mean peak plasma concentration (Cmax) increased linearly as a function of the dose (r = 0.999). The mean area under the plasma concentration-time curve (AUC) from 0 to 16 hours also increased proportionally with dose escalation (r = 0.998). However, the clearance was constant over the specific dose interval. In the multiple-dose PK study, the trough and average concentrations remained low. The mean AUC, half-life, Cmax, time to Cmax, and the volume of distribution on the first day were similar to those on the last day. All subjects tolerated the treatments well. Most UANL-associated adverse events varied from mild to moderate.Conclusions: UANL exhibits relatively linear PK behavior with dose levels from 37 mg/m2 to 98 mg/m2. No drug accumulation was observed with repeated doses of UANL. The intravenous infusion of UANL was well tolerated by healthy volunteers and patients with advanced tumors.Keywords: ursolic acid, nanoliposomes, pharmacokinetics, solid tumor, ultra-performance liquid chromatography, tandem mass spectrometry |
| format |
article |
| author |
Ying G Wang H Zhao C Yan Z Qian Z Zhu Z |
| author_facet |
Ying G Wang H Zhao C Yan Z Qian Z Zhu Z |
| author_sort |
Ying G |
| title |
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| title_short |
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| title_full |
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| title_fullStr |
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| title_full_unstemmed |
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| title_sort |
phase i pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/269f070c524c4278a455d6c1af6beeda |
| work_keys_str_mv |
AT yingg aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT wangh aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT zhaoc aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT yanz aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT qianz aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT zhuz aphaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT yingg phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT wangh phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT zhaoc phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT yanz phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT qianz phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors AT zhuz phaseipharmacokineticstudyofursolicacidnanoliposomesinhealthyvolunteersandpatientswithadvancedsolidtumors |
| _version_ |
1718400758449176576 |